A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)

Article English OPEN
Ramanan, A. V. ; Benton, D. ; Dick, A. D. ; Compeyrot-Lacassagne, S. ; Woo, P. ; Edelsten, C. ; Hardwick, B. ; Hickey, H. ; Jones, A. ; Beresford, M. W. ; Dawoud, D. ; Hughes, D. (2014)
  • Publisher: BioMed Central
  • Journal: Trials, volume 15, pages 14-14 (eissn: 1745-6215)
  • Related identifiers: pmc: PMC3892031, doi: 10.1186/1745-6215-15-14
  • Subject: Safety | Rheumatology | Methotrexate | Study Protocol | Ophthalmology | Juvenile idiopathic arthritis | Uveitis | Adalimumab | Paediatric
    mesheuropmc: skin and connective tissue diseases | genetic structures | musculoskeletal diseases

Background: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Children with JIA are at risk of inflammation of the uvea in the eye (uveitis). Overall, 20% to 25% of paediatric uveitis is associated with JIA. Major risk factors for dev... View more
Share - Bookmark